Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
The company is advancing a pipeline for C3G/IC-MPGN in nephrology, aligning with Rare Diseases as an investable category.
|
$5.17B |
$40.90
+0.06%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$5.14B |
$29.30
+7.15%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$5.10B |
$49.92
-0.16%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$5.03B |
$97.96
+2.19%
|
|
GHC
Graham Holdings Company
Healthcare Services & Facilities reflecting CSI Pharmacy and patient services.
|
$5.03B |
$1155.14
+2.89%
|
|
MIR
Mirion Technologies, Inc.
Core business: Mirion designs and manufactures medical devices and biometric sensing equipment used in radiology, radiation therapy, and nuclear medicine.
|
$5.00B |
$19.73
+2.36%
|
|
GNTX
Gentex Corporation
Medical Devices & Biometrics covers EyeLock iris biometrics and eSight medical device initiatives tied to Gentex's diversification.
|
$4.95B |
$22.62
+3.67%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$4.86B |
$20.49
-2.10%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$4.86B |
$46.15
+4.97%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$4.74B |
$52.65
-0.09%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$4.73B |
$99.53
+0.20%
|
|
STVN
Stevanato Group S.p.A.
Directly manufactures Prefillable Syringes used for sterile biologic and small-molecule injections.
|
$4.70B |
$15.59
+3.73%
|
|
RDNT
RadNet, Inc.
RadNet operates outpatient imaging centers/ASC, providing diagnostic imaging services.
|
$4.66B |
$60.34
+0.41%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.65B |
$7.74
-0.96%
|
|
SHC
Sotera Health Company
Nelson Labs provides outsourced microbiological and analytical chemistry testing plus regulatory advisory services.
|
$4.63B |
$16.31
+3.03%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$4.61B |
$59.69
+2.16%
|
|
NOVT
Novanta Inc.
Medical Devices & Biometrics aligning with their focus on medical devices and biometric sensing technologies.
|
$4.61B |
$128.85
+2.35%
|
|
NVST
Envista Holdings Corp
Envista directly manufactures dental equipment, including implants and aligners, a core product line.
|
$4.58B |
$27.84
+3.36%
|
|
OPCH
Option Care Health, Inc.
OPCH delivers home health infusion and hospice-related services in patients' homes, aligning with home health care offerings.
|
$4.57B |
$28.82
+1.71%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.56B |
$231.93
+3.89%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$4.46B |
$14.46
+0.03%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$4.37B |
$13.90
+6.19%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
ALHC
Alignment Healthcare, Inc.
Alignment provides Medicare Advantage health insurance via its integrated health plan.
|
$4.25B |
$21.22
+1.92%
|
|
MMSI
Merit Medical Systems, Inc.
Directly tied to Merit's core cardiology/interventional devices, including cardiac intervention products and lead-management solutions (Cook acquisition).
|
$4.21B |
$70.91
+1.16%
|
|
OSCR
Oscar Health, Inc.
Core product is health insurance plans via ACA marketplace and employer-based offerings, generating premium-based revenue.
|
$4.18B |
$15.80
+1.12%
|
|
CNO
CNO Financial Group, Inc.
Health insurance offerings (including Medicare Supplement) are a core segment.
|
$4.16B |
$43.65
+1.55%
|
|
INDV
Indivior Pharmaceuticals Inc
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.08B |
$32.68
+3.71%
|
|
IRTC
iRhythm Technologies, Inc.
Direct product: iRhythm's patch-based patient monitoring device and associated software for continuous cardiac monitoring.
|
$4.04B |
$125.38
+2.26%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$4.00B |
$93.22
+0.34%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$3.98B |
$35.19
-0.90%
|
|
TMDX
TransMedics Group, Inc.
TransMedics' Organ Care System (OCS) is a proprietary medical device platform for organ preservation and monitoring.
|
$3.96B |
$115.97
+6.28%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.93B |
$34.69
+4.47%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$3.91B |
$21.16
+0.40%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$3.89B |
$41.01
+5.09%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
DAYBUE (trofinetide) and ACP-101 intranasal carbetocin are peptide therapeutics, supporting a peptide therapeutics business.
|
$3.75B |
$22.16
+4.31%
|
Showing page 8 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
